What is the recommended dose of aximinib/asinib

Asciminib is an ABL1 kinase inhibitor mainly used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in the chronic phase. It prevents the growth of tumor cells by specifically inhibiting the activity of BCR-ABL1 kinase and is one of the targeted drugs for the treatment of Philadelphia chromosome-positive CML.

According to clinical guidance, the recommended dose of aceminib is 40 mg twice daily and should be taken on an empty stomach. That is, take it at least 1 hour before a meal or 2 hours after a meal to ensure the absorption effect of the drug. Aceminib treats CML by selectively inhibiting the BCR-ABL1 tyrosine kinase, thereby preventing the proliferation of leukemia cells. Compared with other ABL1 inhibitors, Aceminib is more precise in targeting and can effectively reduce the occurrence of side effects.

During the treatment process, patients should follow the doctor's prescription instructions and take the recommended dosage strictly. If any discomfort occurs, you should promptly report to your doctor and adjust the dosage or discontinue the medication according to your doctor's advice. In addition, the dosage of aximini may be adjusted individually based on factors such as the patient's condition and drug resistance, so regular blood tests and physician evaluation are essential.

It should be noted that Aceminib is a prescription drug and patients cannot increase or decrease the dose on their own. If the patient misses a dose, it is recommended to take it as soon as possible on the day you remember. However, if it is close to the next dose time, skip the missed dose and take the medication at the regular time to avoid doubling the dose. Strict compliance with drug dosage regulations is an important measure to ensure efficacy and safety.

In summary, the recommended dose of aceminib is40 mg taken twice daily on an empty stomach. Strictly following the drug dosage and taking requirements can effectively improve the treatment effect and help patients better manage chronic myelogenous leukemia.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib